Novo Nordisk and ZymoGenetics begin clinical tests of potential cancer drug  

Novo Nordisk is teaming up with partly owned US subsidiary ZymoGenetics to conduct clinical tests on IL-21
The financial weekly newsletter Økonomisk Ugebrev writes that Novo Nordisk is conducting its first clinical tests of a cancer drug. The company is reportedly gearing up to move into this new therapy area and if all goes to plan, human trials of the drug will commence in 2004. Novo Nordisk has made a deal with the partly owned US subsidiary ZymoGenetics on taking forward the clinical trial work on the drug, which is codenamed IL-21. In animal models, IL-21 has already been shown effective in attacking and destroying cancer cells.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×